SSc-ILD: Combination of rituximab and mycophenolate mofetil not superior to treatment with either agent alone

Combining rituximab with mycophenolate mofetil in patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) did not significantly improve lung function compared to monotherapy. The proportion of patients with a percent predicted forced vital capacity (%pFVC) increase >3.3% was, however, numerically higher with the combination therapy. Using the EUSTAR database, a cohort study was conducted to investigate the efficacy of combination therapy with rituximab plus mycophenolate mofetil versus treatment with either agent alone in patients with SSc-ILD [1]. Mixed-effect models were used to compare the changes in %pFVC and diffusing capacity of the lung for carbon monoxide (DLCO) on the different regimens over 12 months. The study included 425 patients, distributed in 3 treatment groups with varying sample sizes: MMF (n=250), rituximab (n=154), and combination therapy (n=21). Dr Devis Benfaremo (Università Politecnica delle Marche...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 20 June 20258 August 2025